Competitive intelligence
Side-by-side comparison
Up to six companies on the same rows. Empty cells say what is missing rather than hiding it.
2 of 6 columns
Comparison
| Attribute | Superluminal Medicines, Inc.7.2remove | Trace Biosciences Inc.7.4remove |
|---|---|---|
| Signal scores | ||
| Radar composite | 7.2 | 7.4 |
| IPO signal score | 14.4 | 14.8 |
| Tokenization signal score | 0.0 | 0.0 |
| On-chain readiness | 0.0 | 0.0 |
| Momentum | ACCELERATING+8.7 | STABLE+3.4 |
| Company | ||
| Stage | private | private |
| Sector | Technology | Technology |
| Headquarters | BOSTON, United States | BEAVERTON, United States |
| Founded | 2023 | 2021 |
| Employees | not on record | not on record |
| Capital | ||
| Latest valuation | not on record | not on record |
| Total funding | $65M | $8M |
| Latest round | Private Placement $65M | Private Placement $8M |
| Investors on record | 0 | 0 |
| Evidence | ||
| Institutional relationships | 0 | 0 |
| Active signals | 2 | 1 |
| Confidence | 55% | 53% |
IPO Radar is a research and intelligence tool. Scores are signal scores derived from public evidence — they are not calibrated probabilities and not investment advice. FACT, INFERENCE and PREDICTION are kept separate, and every event links to its source.